Efficacy and safety of home-based transcranial direct current stimulation (tDCS) on patients with depressive disorders: a systematic review and meta-analysis of randomized clinical trials Authors: Reza Moshfeghinia, Sanaz Bordbar, Yasamin Roointanpour, Melika Arab Bafrani, Mohammadreza Shalbafan Published: 2025 ABSTRACT AbstractDepressive disorders, including major depressive disorder, impair functioning and affect 280 million people globally. Traditional treatments are not fully effective. Transcranial direct current stimulation (tDCS) offers a noninvasive alternative. Home-based tDCS shows promise for treating depression, requiring systematic review to assess its reliability and efficacy. Six digital databases (Scopus, PubMed, Web of Science, Cochrane, PsycINFO, and CINAHL Complete) were searched for English-language records from inception to November 2024. Inclusion criteria involved randomized controlled trials (RCTs) assessing the effect of home-based tDCS on patients with depressive disorders. The Cochrane Collaboration’s tool was used to evaluate the quality of the included studies. From an initial 507 studies, five RCTs with 415 depressed patients were included. Four studies analyzed Montgomery–Åsberg Depression Rating Scale (MADRS) scores in 269 patients, revealing that active tDCS significantly reduced depression scores compared to sham (weighted mean difference [WMD]: − 2.74 [–4.19, − 1.29], I² = 0.00%). Similarly, four studies involving 438 patients assessed Hamilton Depression Rating Scale (HAM-D) scores, showing that active tDCS led to greater reductions in depression scores than sham (WMD: − 2.24 [–4.16, − 1.49], I² = 46.63%). In addition, two studies with 211 participants assessed Hamilton Anxiety Rating Scale (HAM-A) scores, indicating that active home-based tDCS significantly reduced anxiety symptoms compared to sham (WMD: − 1.97 [–3.37, − 0.58], I² = 0.00%). Reported adverse effects of home-based tDCS included skin lesions, pain, burning sensations, increased sensitivity, redness, and mild headaches. This systematic review and meta-analysis showed that home-based tDCS effectively reduces depression and anxiety scores, with significant improvements on MADRS, HAM-D, and HAM-A scales. Future research should include larger samples, better adherence, and long-term efficacy assessments.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-28648-5.Keywords: TDCS, Home-based tDCS, Depression, Anxiety, Non-invasive brain stimulationSubject terms: Depression, Human behaviour, Biological therapy Introduction Depressive disorders, including major depressive disorder (MDD), are prevalent mental health conditions characterized by psychological, cognitive, and functional impairments1,2. Globally, depression affects approximately 280 million individuals3. Treatment approaches for MDD are broadly divided into pharmacological and non-pharmacological strategies. Non-pharmacological interventions encompass psychotherapeutic approaches, behavioral and physical interventions, neuromodulation techniques, and complementary or alternative medicine4,5. Despite these diverse options, neither pharmacological nor non-pharmacological treatments provide consistently satisfactory outcomes6,7. Pharmacological therapies are frequently associated with partial response and high relapse rates, whereas non-pharmacological interventions often demonstrate variable efficacy and face methodological and accessibility challenges4,8. Non-invasive brain stimulation (NIBS), a form of neuromodulation, seeks to modulate cortical excitability9,10. Among these techniques, transcranial direct current stimulation (tDCS) has gained attention11. tDCS delivers low-intensity electrical currents through scalp electrodes to influence brain activity12. Evidence supports its potential effectiveness not only in depressive disorders but also in conditions such as attention deficit hyperactivity disorder (ADHD), anxiety, and nicotine dependence13–16. For example, Brunoni et al. demonstrated that even a single session of tDCS could alter emotional processing in patients with MDD. Compared to other non-invasive neuromodulation methods, tDCS is generally well tolerated, associated with fewer adverse effects, and more feasible for patients17–19. Although tDCS devices are considered safe20, effective treatment typically requires repeated daily sessions. Traditionally, this necessitated frequent hospital visits and supervision by healthcare professionals21,22. To overcome these limitations, more portable and user-friendly systems have been developed, enabling patients to use tDCS independently at home. Home-based tDCS represents a self-administered, unsupervised approach that offers a potentially convenient and feasible alternative for managing depressive disorders23. Case series suggest that home-based tDCS, when combined with standard therapies, may improve both depressive and anxiety symptoms24. Additionally, several single-arm trials have reported promising outcomes in patients with MDD25,26. This systematic review and meta-analysis aims to evaluate the efficacy and safety of home-based tDCS in patients with depressive disorders. Specifically, it synthesizes evidence from randomized controlled trials (RCTs) to determine its impact on depressive symptoms and its safety profile compared with sham stimulation or other interventions. Methods To assess the effect of home-based tDCS on patients with depressive disorders, 2020 Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines were used for this systematic review and meta-analysis27 (Supplementary Material, Table S1). The research plan was officially recorded in the International Prospective Register of Systematic Reviews (PROSPERO) with the assigned registration number CRD42024545174. Search strategy A comprehensive search strategy was developed using the primary keywords “tDCS,” “depression,” and “home-based,” along with their corresponding MeSH terms and synonyms. Six electronic databases—Scopus, PubMed, Web of Science, Cochrane, PsycINFO, and CINAHL—were searched for English-language records published up to November 2024. The full search strategies for each database are provided in the Supplementary Material. To ensure completeness, the reference lists of included studies and relevant reviews were also screened. In addition, grey literature was explored through a manual search in Google Scholar. Eligibility criteria In this study, we included RCTs that examined home-based transcranial direct current stimulation (tDCS) in patients with depressive disorders. Based on the PICO framework, the eligibility criteria were as follows: (P) Population: individuals diagnosed with depressive disorders, ranging from mild depression to major depressive disorder (MDD); (I) Intervention: home-based tDCS; (C) Comparison: sham tDCS; and (O) Outcomes: depressive and anxiety symptoms assessed using validated scales (e.g., Montgomery–Åsberg Depression Rating Scale (MADRS), the Hamilton Depression Rating Scale (HAM-D), and the Hamilton Anxiety Rating Scale (HAM-A) questionnaire) as well as reported side effects. We excluded studies that1used qualitative methods2; focused on conditions other than depression3; employed non-experimental designs (e.g., case reports, observational studies, reviews, conference presentations, editorials, or animal research)4; provided insufficient data; or5 were redundant or involved overlapping participant samples. Study selection Two researchers, SB and YR, independently reviewed eligible studies using set inclusion and exclusion criteria. They obtained the full texts of selected studies for detailed analysis. Any disagreements about study design or methodology were resolved by the senior researcher, RM, who made the final decisions on inclusion or exclusion. Interrater agreement between the two reviewers was quantified using Cohen’s kappa (κ = 0.78), indicating substantial agreement. Data extraction The comprehensive attributes extracted from the included studies included the initial author, country, study design, overall and specific sample sizes of the groups, details of the interventions, control conditions, and reported side effects. Data collection from the integrated articles was conducted independently by SB and MA. Any disagreements were addressed through discussions with a third author, RM. Risk of bias assessment The assessment of study quality involves utilizing the Cochrane tool28. To measure the risk of bias and overall study quality. The Cochrane Risk of Bias Tool for Randomized Trials also referred to as the Risk of Bias-2 (ROB-2) tool29, is structured into five domains (D) for the comprehensive evaluation of bias. The categorization of study quality encompasses three groups: high, some concerns, and low risk of bias score. Certainty of evidence assessment The certainty of evidence across the primary outcomes was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Following GRADE methodology, we assessed each outcome for potential limitations in study design and execution (risk of bias), inconsistency of results, indirectness of evidence, imprecision of estimates, and risk of publication bias. Based on these domains, the certainty of evidence was rated as high, moderate, low, or very low. Quantitative analysis In examining the home-based tDCS and sham groups, we determined the mean difference (MD) and the standard deviation (SD) of depression scores based on different assessment tools for depression which had sufficient data for analysis, including the MADRS, the HAM-D, and the HAM-A questionnaire. The overall effect magnitude (weighted mean difference (WMD)) was derived from these values. SD was also computed using the standard error (SE) and 95% confidence interval (CI), following the procedure outlined by Hozo et al.30. Utilizing a random-effects model (restricted maximum likelihood (REML)), we combined the WMDs. The chi-squared test and I2 were used for assessing the heterogeneity among the studies. To evaluate the risk of publication bias, Egger’s test and Begg’s test were applied. A funnel plot, plotting was used to visually represent publication bias. The symmetrical funnel-shaped distribution suggested a low risk of publication bias, while an asymmetrical distribution suggested a high risk. Additionally, a leave-one-out sensitivity analysis was performed to test the robustness of the pooled effect size. When each study was sequentially removed, the overall findings remained consistent. All analyses were conducted using Stata software-17, and statistical significance was considered for p-values below 0.05. Results Selection of studies The initial search yielded 507 articles. After removing 281 duplicate articles using EndNote software, we screened the titles and abstracts of the remaining 226 articles and excluded 201 of them. We then assessed the full texts of the 25 articles that met the eligibility criteria and determined that 20 of them did not meet the inclusion criteria. Ultimately, five articles22,23,31–33 were included in the systematic review (Fig. 1). PRISMA of the included studies. Study characteristics Table 1 summarizes the characteristics of the five included studies22,23,31–33, which were published from 2022 to 2024. In total 415 depressed patients (199 in the treatment group and 216 in the control group) were included. Participants in four studies were involved with MDD and in one study patients with both mild cognitive impairment (MCI) and depressive disorders31 were investigated. The mean age of participants varied from 28.5 to 76.1 years. Two of the included studies were reported from the South Korea22,31, and all of the studies consisted of both sexes. Outcome measures in these studies were MADRS, HAM-D and HAM-A. Anodal tDCS was administered at an intensity of 2 mA and for 30 min during 6 sessions for all studies (except for one study33 with 10 weeks). The electrode regions for the Anode and Cathode locations were F3 and F4, respectively for all studies. Table 1General characteristics of all included studies.AuthorCountryConditionMean Age (SD)Case (M/F)Control (M/F)Duration (min)Power (mA)LocationDuration (week)Side events Oh et al., 202222South KoreaMDDActive: 29.7 (11.6)Sham: 28.5 (11)Active: 20 (10/10)Sham: 25 (15/10)302Cathode: F4, Anode: F36mild headache in one patient.Mild electrical burns in two patients in the active group.Kim et al., 202331South KoreaDepression and MCIActive:76.1 (7.4)Sham: 73.1 (6.3)Active: 14 (6/8)Sham: 23 (7/16)302Cathode: F4, Anode: F3.6NoneKumpf et al., 202332GermanyMDDActive: 35.80(10.83)Sham: 38.67(13.62)Active:5(4/1)Sham: 6 (3/3)302Cathode: F4, Anode: F36One patient experienced increased burning and pain, another had light flashes during stimulation, and one showed heightened skin sensitivity; follow-up was inadequate for other patients.Borrione et al., 202423BrazilMDDActive: 38.8 (9.1)Sham: 39.2 (8.8)Active: 73 (5/68)Sham: 73 (15/58)302Cathode: F4, Anode: F36Some local skin redness, heat, or burning sensations were reported in 2 groups. One nonfatal suicide attempt occurred in the active tDCS group. Woodham et al. 202433UKMDDActive: 37.1 (11.1)Sham: 38.3 (10.9)Active: 87 (32/54)Sham: 87 (21/66)302Cathode: F4, Anode: F310Adverse events were reported in both groups, but only trouble concentrating and skin redness were more prevalent in the active group.Abbreviations: M, Male; F, Female, mA, Milly ampere; MCI, Mild cognitive impairment; MDD, Major depressive disorder;. General characteristics of all included studies. Active: 29.7 (11.6) Sham: 28.5 (11) mild headache in one patient. Mild electrical burns in two patients in the active group. Active:76.1 (7.4) Sham: 73.1 (6.3) Active: 35.80(10.83) Sham: 38.67(13.62) Active: 5(4/1) Active: 38.8 (9.1) Sham: 39.2 (8.8) Active: 37.1 (11.1) Sham: 38.3 (10.9) Abbreviations: M, Male; F, Female, mA, Milly ampere; MCI, Mild cognitive impairment; MDD, Major depressive disorder;. Risk of bias assessment Of all five included studies three studies showed a low risk of bias23,32,33 and another two studies22,31 showed some concerns scores which are both in the missing data report (Fig. 2). Risk of bias assessment of all included studies based on the ROB-2 tool. Synthesis of results In total 415 depressed patients (199 in the treatment group and 216 in the control group) were included in meta-analysis. Meta-analysis was performed based on different tools for depression which had sufficient data for analysis including MADRS, HAM-D, and the HAM-A questionnaire. For analysis of the MADRS tool four studies22,31–33 with 269 depressed patients (126 in the treatment group and 143 in the control group) in the analysis. Analysis showed that active tDCS showed a greater decrease in depression score than sham tDCS (WMD: −2.74 [−4.19, −1.29], I2: 0.00%). Sensitivity analysis showed the exclusion of the Woodham et al.33 had more effect on the pooled result (WMD: −3.53 [−5.90, −1.15]). Also, both funnel plot and Egger (p = 0.78) and Begg (p = 0.73) tests showed no publication bias (Fig. 3). Given concerns about potential bias in the study by Kim et al.31. (patients with MCI + depression), we conducted a sensitivity analysis excluding this trial. Three RCTs22,32,33 with a total of 220 participants were included in this re-analysis. The results remained consistent, showing that active tDCS produced significantly greater reductions in MADRS scores compared to sham (WMD: − 2.86 [–4.35, − 1.36], I² = 0.00%) (Supplementary Material, Figure S1). Meta-analysis of the depression for MADRS tool (Upper). Publication bias (Lower). For analysis of the HAM-D tool four studies22,23,31,33 with 438 depressed patients (194 in the treatment group and 210 in the control group) in the analysis. Analysis showed that active tDCS showed more decrease in depression score than sham tDCS (WMD: −2.24 [−4.16, −1.49], I2: 46.63%). Sensitivity analysis showed the exclusion of the Borrione et al.23 had more effect on the pooled result (WMD: −3.41 [−5.31, −1.52]). Also, both funnel plot and Egger (p = 0.40) and Begg (p = 0.73) tests showed no publication bias (Fig. 4). A sensitivity analysis excluding the Kim et al.31 study (MCI + depression) was performed. Three RCTs22,23,33 with 358 participants were re-analyzed. The pooled effect size remained similar (WMD = − 2.32 [–4.72, 0.07]; p = 0.06). Heterogeneity also increased (I² = 60.72%) compared with the original analysis including Kim (I² = 46.63%) (Supplementary Material, Figure S2). Meta-analysis of the depression for HAM-D tool (Upper). Publication bias (Lower). An analysis of the HAM-A from two studies31,33, involving 211 participants (101 in the intervention group and 110 in the control group), indicated a reduction in HAM-A scores with active home-based tDCS in comparison to sham tDCS (WMD: −1.97 [− 3.37, − 0.58], I² = 0.0%). The funnel plot revealed an asymmetric distribution but did not suggest publication bias (Fig. 5). Meta-analysis of the depression for HAM-A tool (Upper). Publication bias (Lower). Assessment of reported adverse events of home-based tDCS, showed skin lesions, pain, burning sensation, increase in skin sensitivity, redness, and mild headache. One study33 utilized the tDCS Adverse Events Questionnaire34 to compare the differences in adverse events between the active and sham groups. The results showed that only the scores for trouble concentrating and skin redness were significantly higher in the active group (Table 1). In addition, a GRADE assessment was performed to evaluate the certainty of evidence across the main outcomes. The certainty of evidence was rated as moderate for reductions in depressive symptoms measured by MADRS and HAM-D, indicating that active home-based tDCS probably results in clinically meaningful improvements compared to sham. For anxiety symptoms measured by HAM-A, the certainty was rated as low, reflecting limitations in the available evidence and imprecision of the estimates. Similarly, the certainty of evidence regarding adverse events was judged to be low, as most reported events were mild and inconsistently reported across trials. A detailed Summary of Findings table is provided (Table 2). Table 2Summary of findings and certainty of evidence (GRADE) for Home-Based tDCS in depressive Disorders.OutcomeParticipantsEffect Estimate (95% CI)Certainty of Evidence (GRADE)Interpretation Depression severity (MADRS) 269 (4 RCTs)WMD = − 2.74 [–4.19, − 1.29]⬤⬤⬤◯ Moderate *Active tDCS likely reduces depression scores compared to sham. Depression severity (HAM-D) 438 (4 RCTs)WMD = − 2.24 [–4.16, − 1.49]⬤⬤⬤◯ Moderate *tDCS probably leads to a greater reduction in depression scores. Anxiety severity (HAM-A) 211 (2 RCTs)WMD = − 1.97 [–3.37, − 0.58]⬤⬤◯◯ LowEvidence suggests a small reduction in anxiety, but certainty is limited. Adverse events 415 (5 RCTs)Skin lesions, pain, burning, redness, mild headache⬤⬤◯◯ LowMost adverse events were mild; overall certainty of evidence is low.Abbreviations: HAM-A: Hamilton Depression Rating Scale- Anxiety, HAM-D: Hamilton Depression Rating Scale- Depression, MADRS: Montgomery–Åsberg Depression Rating Scale, RCT: Randomized Clinical Trial, tDCS: Transcranial direct current stimulation.* Downgraded one level for risk of bias and indirectness: As one included study (Kim et al., 2023) enrolled participants with MCI, not MDD. Depression rating scales (HAM-D, MADRS) have not been validated in MCI populations, and treatment responsiveness may differ. These factors increase potential measurement bias and indirectness. Summary of findings and certainty of evidence (GRADE) for Home-Based tDCS in depressive Disorders. Abbreviations: HAM-A: Hamilton Depression Rating Scale- Anxiety, HAM-D: Hamilton Depression Rating Scale- Depression, MADRS: Montgomery–Åsberg Depression Rating Scale, RCT: Randomized Clinical Trial, tDCS: Transcranial direct current stimulation. * Downgraded one level for risk of bias and indirectness: As one included study (Kim et al., 2023) enrolled participants with MCI, not MDD. Depression rating scales (HAM-D, MADRS) have not been validated in MCI populations, and treatment responsiveness may differ. These factors increase potential measurement bias and indirectness. Discussion In this systematic review and meta-analysis, we evaluated the efficacy and safety of home-based tDCS in treating patients with depressive disorders. At first, five studies were included, considering the sesnivity analysis one was excluded, leading to four studies with MDD patients. All articles included both sexes, and the outcomes were measured by MADRS, HAM-D, and HAM-A. Anodal tDCS was administered at an intensity of 2 mA and for 20 min in all studies. Skin lesions, pain, burning sensation, increased skin sensitivity, redness, and mild headache were possible side effects present in the studies. All in all, 415 patients were included. MADRS and HAM-D questionnaires were used to perform meta-analysis. It was indicated that, based on the MADRS analysis on 269 patients, active tDCS showed a greater decrease in depression scores than sham tDCS. It was also indicated that, based on the HAM-D analysis on 438 patients, active tDCS showed a decrease in depression score compared to sham tDCS. Analysis of anxiety (HAM-A) in 211 participants demonstrated a significant reduction compared with sham-tDCS. Since Kim et al.31 involved older adults with MCI and depression, it was excluded to maintain homogeneity. The remaining MDD-only RCTs showed consistent findings, emphasizing the impact of population characteristics and measurement tools on pooled interpretations. MDD is considered a severe psychiatric disorder with a considerable prevalence among adults35. Various treatment methods have been proposed to treat MDD. Antidepressants, electroconvulsive therapy, psychotherapy, and combination therapy have been used. The response to treatment has been inconsistent due to the heterogeneity of this disorder36. As a result, several other non-pharmacological treatment options have been proposed. The use of non-pharmacological treatment (NPTs) has been correlated with better treatment adherence37. Neurostimulation methods are regarded as NPT methods. There are various methods, including TMS, DBS, and tDCS. Compared to other methods, tDCS is portable and can be self-administered25. tDCS delivers a constant, low direct current to the dorsolateral prefrontal cortex (DLPFC), modulating cortical excitability and neural networks, making it suitable for psychiatric disorders38,39. In MDD, the DLPFC is commonly targeted due to its role in working memory, cognitive control, and emotion regulation, with abnormal connectivity linked to depressive symptoms40,41. Its stimulation is considered beneficial for symptom improvement38. Two meta-analyses and one review confirmed the effectiveness of tDCS in MDD, aligning with our findings42–44, though most prior studies focused on clinical settings, highlighting the need to explore home-based applications42. Tele-supervised home-based tDCS, using multi-channel systems and real-time monitoring, has shown promise in efficacy, safety, and patient acceptability45,46, with preliminary effectiveness in reducing MDD symptoms26. However, findings remain heterogeneous. Some studies questioned its effectiveness32, while an RCT showed improvements in subjective depression scores but no significant changes in HAM-D or MMSE, limiting firm conclusions22. tDCS may also offer dual benefits for depression and anxiety when combined with pharmacotherapy and psychotherapy24. Our results showed MDD symptoms were evident via MADRS and HAM-D tests. Although our meta-analysis demonstrated statistically significant reductions in depression scores for both MADRS (WMD: − 2.74) and HAM-D (WMD: − 2.24), these changes often do not meet established thresholds for clinical significance. For MADRS, the lower bounds of the minimal clinically important difference (MCID) range (1.6–1.9) suggest borderline clinical relevance, while higher thresholds (4.9 or above) in certain populations indicate that the observed effect may be insufficient from a clinical perspective47. Similarly, for HAM-D, differences of 2–3 points are considered potentially meaningful by some guidelines; however, observed differences of 4–10 points or effect sizes approaching 0.875 are more likely to reflect minimal clinical improvements48. Therefore, while our findings are statistically significant, they may not necessarily correspond to clinically meaningful changes in patient outcomes. Findings across studies were inconsistent. Some reported no cognitive effects or changes in psychiatric test scores following tDCS49, with symptom improvement not reflected in HAM-D scales50. Others noted changes in MADRS scores without significant differences between active and sham groups51. An RCT in epileptic patients found tDCS safe but ineffective based on Beck Depression Inventory scores52. Similarly, home-based tDCS over the frontal arc showed no significant group differences via HAM-D. In contrast, newer RCTs demonstrated symptom reduction and changes in psychiatric scores, including MADRS33,53, supporting the effectiveness of tDCS in opposition to earlier findings32. Our results did not indicate cognitive enhancement following tDCS in MDD. Findings across studies remain inconsistent. While increased excitability of the targeted region may improve cognitive function54. An RCT in patients with MCI and depression found no superiority of active tDCS over sham in terms of depressive symptoms or neurocognition, despite changes in alpha and beta frequencies linked to cognitive enhancement. However, firm conclusions could not be drawn. Variations in treatment protocols, such as frequency, intensity, stimulation site, duration, and electrode size, may explain these differences31. A recent systematic review also reported no significant cognitive improvement, though verbal memory showed enhancement following active tDCS, so it can be concluded that the effectiveness of tDCS might depend on the ability measured and the tests used43. Regarding side effects, findings were heterogeneous. While our study reported no severe adverse events, other investigations highlighted concerns. An RCT on 6 weeks of home-based tDCS in MDD patients noted mild dermatological effects, including electrical burns22. Some studies found tDCS had more side effects than antidepressants37, with common adverse events such as headaches, pain, and burning sensations43. Reviews and pilot studies emphasized considerable side effects in home-based applications32, including burning sensations, skin redness, and one nonfatal suicide33. A later randomized trial challenged the safety of home-based prefrontal tDCS, ending prematurely due to adverse events32, and reinforced the need for monitoring55. All in all, it is deduced that the data regarding tDCS treatment does contain certain heterogeneities. The more recent articles indicated its effectiveness, but still with certain adverse effects. And, the use of home-based tDCS is not suggested. The primary limitations of this study include the limited number of included studies and participants, which restricts the generalizability of the findings. Second, the high heterogeneity observed across studies may influence the reliability of the results. Third, while tDCS appears to have a measurable effect, its clinical significance in the HAM-D and MADRS remains to be fully established. Moreover, the quantitative analysis of anxiety outcomes (HAM-A) was based on only two RCTs, which according to the Cochrane Handbook is technically acceptable but provides weak evidence, as more independent studies are generally needed to draw robust conclusions. These findings underscore the need for further research involving larger sample sizes, extended follow-up periods, and standardized outcome measures to better assess whether the observed improvements translate into meaningful benefits for patients in practice. Despite these limitations, the study has several strengths. The analysis is based exclusively on RCTs, which are considered the gold standard for clinical research, thus enhancing the credibility of the findings. The use of WMD analysis provides a robust statistical approach to compare the effects of active versus sham tDCS. Furthermore, all included studies employed a standardized tDCS protocol (2 mA for 30 min, with the cathode at F4 and the anode at F3, over six weeks), ensuring consistency in treatment parameters. This is the first systematic review and meta-analysis to evaluate the efficacy and safety of home-based tDCS using such a consistent methodological approach. Future research should focus on studies with larger sample sizes to enhance the power and generalizability of the findings. Additionally, investigating patient adherence to home-based tDCS treatment will provide insights into the practical implementation of this therapy. Long-term efficacy and follow-up studies are crucial to determine the sustained benefits and safety of home-based tDCS over extended periods. These future directions will help to solidify the role of home-based tDCS in the treatment of depressive disorders and optimize its application in clinical practice. Conclusion This systematic review and meta-analysis, which included 415 patients with depression, demonstrated the efficacy and safety of home-based tDCS. Most participants had Major Depressive Disorder, with ages ranging from 28.5 to 76.1 years, and both sexes were represented. Home-based anodal tDCS (2 mA, 30 min, mainly six sessions) was compared to sham, with outcomes measured using MADRS, HAM-D, and HAM-A. Meta-analysis showed statistically significant reductions in depressive and anxiety symptoms, though effect sizes were modest (WMD − 2.74 for MADRS, − 2.24 for HAM-D, and − 1.97 for HAM-A), which showed significant results but were below the usual clinical significance level. Adverse events were generally mild, including skin irritation and headaches. Overall, the evidence suggests that home-based tDCS can alleviate both depressive and anxiety symptoms; however, heterogeneity across studies and the occurrence of mild to moderate adverse effects warrant caution. More recent trials have indicated potential effectiveness, yet routine use of home-based tDCS cannot currently be recommended. Future research should prioritize larger sample sizes, improved patient adherence, and long-term follow-up to assess sustained efficacy and safety. Moreover, future RCTs should strive for greater homogeneity, with clearly defined subgroups (e.g., Major Depressive Disorder, Bipolar I Disorder, or Bipolar II Disorder) to better determine the efficacy of home-based tDCS across these conditions. Supplementary Information Below is the link to the electronic supplementary material. Supplementary material 1 (DOCX 461.0 kb) Authors’ contributions RM made substantial contributions to the conception and design of the work. SB, YR, and MA have substantial contributions in data gathering. RM analyzed and interpreted the data. RM and MS have major contributions to writing the manuscript. All authors read and approved the final manuscript. Funding The authors disclose receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Iran University of Medical Sciences to MS (Grant no: 1403-4-99-32632). Declarations Competing interests The authors declare no competing interests. Ethics approval and consent to participate The study was approved by the ethics committee of Iran University of Medical Sciences institutional review board (IRB: IR.IUMS.REC.1404.510) and all methods were performed in accordance with the relevant guidelines and regulations. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary material 1 (DOCX 461.0 kb)